-
CSR Summary
Not Available
-
NCT01515423
-
Primary Citation
-
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NamePaliperidone palmitateProduct NameINVEGA SUSTENNA®Therapeutic AreaBehaviors and Mental DisordersEnrollment1429% Female46.9%% WhiteN/A
Product ClassAtypical AntipsychoticsSponsor Protocol NumberR092670PSY3011Data PartnerJohnson & JohnsonCondition StudiedSchizophreniaMean/Median Age (Years)38.6
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2024-0608 : Understanding treatment effects and symptom dynamics in schizophrenia using network analysis
- 2024-0556 : Heterogeneity of treatment effects during guaranteed antipsychotic maintenance treatment in schizophrenia as a window into the mechanisms of treatment
- 2024-0268 : Use of machine learning for discerning prognostic and predictive features in schizophrenia disease and evaluating their generalizability
- 2024-0060 : Using Synthetic Controls to Improve Randomised Controlled Trials for Rare Diseases
- 2024-0008 : Sex differences in antipsychotic efficacy and side-effects in adults with acute exacerbations of schizophrenia: an individual-participant network meta-analysis
- 2023-5195 : Predictive modeling of adverse events and symptoms patterns in large scale clinical trials
- 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment ? An individual participant data meta-analysis
- 2021-4754 : Harnessing clinical trial data to inform real-world clinical decision making in the treatment of schizophrenia
- 2021-4705 : Inflammation and the Metabolic Syndrome in Psychosis
- 2021-4667 : Estimation of Geographic and Demographic Variabilities Associated with Schizophrenia Age of Onset and Duration of Untreated Psychosis